Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Chandra Bhagat Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 5.69%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Chandra Bhagat Pharma's 3-Year ROIIC % or its related term are showing as below:
BOM:542934's 3-Year ROIIC % is ranked better than 59.65% of 114
companies
in the Medical Distribution industry
Industry Median: 2.23
vs BOM:542934: 5.69
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Chandra Bhagat Pharma 3-Year ROIIC % Related Terms
Chandra Bhagat Pharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Chandra Bhagat Pharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542934 vs MCK, COR, CAH: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Chandra Bhagat Pharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's 3-Year ROIIC % falls into.
Chandra Bhagat Pharma's 3-Year ROIIC % for the quarter that ended in Mar. 2026 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 34.46961 (Mar. 2026) - 30.762816 (Mar. 2023) )
/
( 573.153 (Mar. 2026) - 507.953 (Mar. 2023) )
=
3.706794
/
65.2
=
5.69%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Chandra Bhagat Pharma (BOM:542934) has a 3-Year ROIIC % of 5.69 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chandra Bhagat Pharma and its competitors. According to the industry distribution chart, Chandra Bhagat Pharma ranks #46 out of 114 companies in the Medical Distribution industry, placing it in the top 40.4%.
Is Chandra Bhagat Pharma's 3-Year ROIIC % too high?
Chandra Bhagat Pharma's current 3-Year ROIIC % is 5.69. The Medical Distribution industry median 3-Year ROIIC % is 2.23. Chandra Bhagat Pharma's value of 5.69 is 155.2% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #46 out of 114 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's 3-Year ROIIC % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #46 out of 114 companies for 3-Year ROIIC %. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median 3-Year ROIIC % is 2.23. Chandra Bhagat Pharma's value of 5.69 is 155.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.23, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current 3-Year ROIIC % of 5.69 is 155.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current 3-Year ROIIC % is 5.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹67.23, compared to a current price of ₹50.40 — trading 25% below its estimated fair value. The current 3-Year ROIIC % is 5.69 and 155.2% above the Medical Distribution industry median of 2.23. Chandra Bhagat Pharma's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current 3-Year ROIIC % is 5.69 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹50.40 is trading 25% below its estimated GF Value™ of ₹67.23.
GuruFocus considers Chandra Bhagat Pharma to be Modestly Undervalued.
Key valuation signals for BOM:542934:
3-Year ROIIC %: 5.69
GF Value™: ₹67.23 vs. price of ₹50.40 (25% below fair value)
Industry Position: 155.2% above the Medical Distribution median (#46 of 114)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
66GF Score
Get the complete analysis for BOM:542934
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
